SWK — Investor Presentation (March 2025)
28 slides from SWK's investor presentation, Mar 20, 2025

Slide 1: Collaborative Approach to Life Science Financing Shareholder Presentation March 2025
1 Collaborative Approach to Life Science Financing Shareholder Presentation March 2025

Slide 2: Forward-looking and Cautionary Statements
2 Forward-looking and Cautionary Statements Statements in this presentation that are not strictly historical, and any statements regarding events or developments that we believe or anticipate will or may occur in the future are "forward- looking" statements within the meaning of the federal securiti

Slide 3: SWK Holdings - Overview
SWK Holdings - Overview 3 Underserved, High- Need Market Demonstrated Success, Attractive Returns Focus on Shareholder Returns Custom financing solutions for commercial-stage healthcare companies and royalty owners • SWK targets $5M to $25M financings, a market niche that is less competitive and gen

Slide 4: Operating Segments
4 Operating Segments LIFE SCIENCE SPECIALTY FINANCE MOD3 Pharma • Senior secured term loans • Royalties • Synthetic royalties • Hybrid structures • CDMO and CMO services • Orally inhaled and nasal drug delivery solutions • Strategic partnership SWK operates through two segments: Life Science Special

Slide 5: Why Life Science Finance?
5 Why Life Science Finance? Tap into underlying demand that is pervasive, growing, and minimally correlated with economic cycles • Healthcare spend is large and increasing, representing 20% of U.S. GDP; forecast to grow at a 5% CAGR through 20301 • Sector has demonstrated durability as S&P 500 sales

Slide 6: Value Creation Strategy
6 Value Creation Strategy SWK believes this strategy will continue to achieve a 10%+ book value per share CAGR Deploy balance sheet capital into secured financing portfolio • SWK has established reputation as a go-to capital provider in our market segment • Majority of financings structured with war

Slide 7: Book Value Components
7 Book Value Components Tangible Finance Book Value / Share = $21.15 • Excludes value of deferred tax asset and Enteris PP&E • SWK’s targets 10%+ CAGR of tangible finance book value / share Plus: Enteris Biopharma Net Book Value / Share = $0.39 • Strategic partner has option to purchase certain prop

Slide 8: Corporate Milestones
8 Corporate Milestones 2019 17th partner exit realized, bringing the weighted avg. IRR on all exits to 20% Acquired Enteris BioPharma Ended year with $178.7M investment assets 2020 Uplisted to Nasdaq and added to Russell 2000 Index Ended year with $212.5M investment assets 2022 Reconstit

Slide 9: Fourth Quarter 2024 Recap
Fourth Quarter 2024 Recap 9CONFIDENTIAL CORPORATE UPDATES FINANCE RECEIVABLES UPDATES • During the fourth quarter of 2024, SWK repurchased 50K shares of stock for a total cost of $0.8M • For FY 2024, SWK repurchased 353K shares of stock for a total cost of $6.0M • Reduced non-accrual balance from $2

Slide 10: Finance Segment Portfolio Overview: 4Q24
10 Finance Segment Portfolio Overview: 4Q24 1) Includes public company warrants and shares; private warrants carried at zero value 2) Excludes non-accruals. 3) As of March 2025 • Gross Finance Receivables: $289.0M • Gross Total Investment Assets: $294.0M1 • Allowance for Loan Loss: $11.2M Financing

Slide 11: Financial Snapshot
$237.9 $290.2 $294.0 2022 2023 2024 Gross Total Investments Assets ($ in millions; at end of period; gross of/before CECL) $41.5 $37.8 $45.0 2022 2023 2024 Total Revenue ($ in millions) 11 Financial Snapshot 1) Eliminates provision for income taxes, Enteris intangibles amortization, and non-cash mar

Slide 12: Attractive Portfolio Yields
12 Attractive Portfolio Yields SWK Targets Low-to-Mid Teens Effective Yields1 4Q24 Finance Segment Effective Yield was 15.5% 1) Effective yield is the rate at which income is expected to be recognized pursuant to the Company’s revenue recognition policies, if all payments are received pursuant to th

Slide 13: Attractive Portfolio Yields: Realized vs. Effective Yield
13.9% 14.2% 14.3% 13.9% 15.5% 14.5% 14.0% 14.4% 14.2% 14.6% 14.6% 15.5% 22.5% 15.0% 17.5% 11.0% 15.3% 15.4% 14.7% 14.1% 15.2% 15.4% 13.8% 14.7% 1Q22 2Q22 3Q22 4Q22 1Q23 2Q23 3Q23 4Q23 1Q24 2Q24 3Q24 4Q24 Realized Yield vs. Effective Yield1 (at end of period) Effective Yield Realized Yield 13 Attract

Slide 14: Current Structured Credit Portfolio
Current Structured Credit Portfolio Biotricity 12.27.2021 $12.0 million Structured Credit NeoLight 02.17.2023 $5.0 million Structured Credit 14 4WEB Medical 07.01.2021 $20.0 million Structured Credit eTon Pharmaceuticals 11.14.2019 $30.0 million Structured Credit Nicoya 10.13.2023 $6.0 million Struc

Slide 15: Current Royalty Portfolio
15 Current Royalty Portfolio Relief Therapeutics 08.02.2024 $11.0 million Royalty Portfolio Acquisition ForFivo (IntelGenx) 08.05.2016 $6.0 million Royalty Acquisition Ideal Implant 04.27.2021 $5.0 million Reorg Synthetic Royalty Financing Best ABT 11.12.2018 $5.8 million Reorg Royalty Coflex & Kybe

Slide 16: Portfolio Realizations Exit History
16 Portfolio Realizations Exit History 12 Yrs. Exited Deals 38 Exits Cash Deployed $432M Cash Returned $619M MOIC 1.43x IRR 17.0% Figures reflective of SWKH balance sheet (i.e., excludes managed/partner transactions) ($s in Ms) Date Cash Investments # Security Invested Paid Off Invested Received MOI

Slide 17: Portfolio Realizations to Strategic Buyers
17 Portfolio Realizations to Strategic Buyers Realizations to strategic buyers demonstrated an average 26% LTV (excl. workouts) of SWK’s original loan value 79% of businesses were not profitable at time of sale, validating SWK’s revenue and IP-based underwriting methodology Workouts exited to

Slide 18: SWK Sourcing
18 SWK Sourcing • Cultivates and maintains a diverse array of longstanding, proprietary deal sources • Consistently sources over 100 actionable investment opportunities per year • Maintains disciplined “look-to-book” ratio of approximately 2-3% Intermediated 12% Hybrid 50% Proprietary 38% 2024 Total

Slide 19: Financing Structures
Financing Structures 19 Product Acquisition • Primarily first lien, senior secured, floating rate loans • Typically include covenants, prepayment penalties, origination and exit fees, and warrant coverage • Provide working capital to support product commercialization and M&A Hybrid Financing Synthet

Slide 20: Historical Financing: Narcan Royalty
Historical Financing: Narcan Royalty 20 OPPORTUNITY SOLUTION • Opiant is a publicly-traded drug development company that receives a royalty on Narcan for developing the drug’s unique formulation – Novel formulation has a faster time to onset and more convenient and safer administration • Opiant need

Slide 21: Historical Financing: Galil Medical
Historical Financing: Galil Medical 21 OPPORTUNITY SOLUTION • In 2014, Galil was on the cusp of accelerating revenue growth, but was not yet cash-flow positive and could not tap traditional financing channels • Galil needed additional capital to run clinical trials and expand its sales force • In De

Slide 22: MOD3 Pharma Corporate Overview
22 MOD3 Pharma Corporate Overview CDMO Platform Revenue-generating CDMO platform Strategic Partnership • Revenue model: – Formulation and development work – Clinical trial material and drug manufacturing • Upgraded high potency manufacturing suite operational in 2021 • Focused on Phase I and Phase I

Slide 23: Leadership Team
23 Leadership Team Jody Staggs President and CEO • Joined in 2015 • Co-founded PBS Capital Management, predecessor to SWK • Prior to PBS, served as Senior Portfolio Analyst at Highland Capital Management • Investing experience in multiple asset classes Dr. Paul Shields MOD3 Pharma subsidiary CEO • J

Slide 24: Why Invest in SWKH – Attractive Risk Reward Scenario
Why Invest in SWKH – Attractive Risk Reward Scenario 24 Shareholder Return Focused • SWK story is not widely known, having uplisted to Nasdaq without benefit of traditional IPO • Analyst coverage and proactive investor relations effort have helped to increase SWK’s visibility • With a Book Value per

Slide 25: Reconciliation of Non-GAAP Adjusted Net Income
25 Reconciliation of Non-GAAP Adjusted Net Income The following table provides a reconciliation of SWK's reported (GAAP) consolidated net income to SWK's adjusted consolidated net income (Non-GAAP) for the periods denoted in the table. The table eliminates provisions for income taxes, non-cash mar

Slide 26: Reconciliation of Non-GAAP Specialty Finance Net Income
26 Reconciliation of Non-GAAP Specialty Finance Net Income The following table provides a reconciliation of SWK's consolidated adjusted income before provision for income taxes, listed in the table above, to the non-GAAP adjusted net income for the specialty finance business for the periods denote

Slide 27: Contact Information
27 Contact Information CONFIDENTIAL SWK Senior Management Investor & Media Relations: Alliance Advisors IR • Jody Staggs: ̶ Phone: 972.687.7252 ̶ Email: jstaggs@swkhold.com • Office address: 5956 Sherry Lane, Unit 650 Dallas, TX 75225 • Website: www.swkhold.com • Susan Xu: ̶ Phone: 778.323.0959 ̶ Em

Slide 28: Collaborative Approach to Life Science Financing
28 Collaborative Approach to Life Science Financing
Source: SEC EDGAR · 8-K filed Mar 20, 2025
More decks from SWK Holdings Corp
Q3 2025 Earnings Presentation29 slides · Nov 7, 2025
Merger or Acquisition (October 2025)7 slides · Oct 14, 2025
Merger or Acquisition (October 2025)12 slides · Oct 10, 2025
Q2 2025 Earnings Presentation23 slides · Aug 14, 2025
Q1 2025 Earnings Presentation31 slides · May 15, 2025
Investor Presentation (November 2024)28 slides · Nov 15, 2024